Clinical Trials in Los Angeles

Showing 14921-14940 of 16,901 trials

Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

NCT01163721

This study enrolled participants with inadequately controlled type 2 diabetes mellitus (T2DM) despite non-insulin antidiabetic therapy in addition to diet and exercise, and would have benefited from additional control of blood glucose levels. The study assessed the metabolic effects of ranolazine, including its effect in lowering glycosylated hemoglobin A1c (HbA1c), and lowering glucose while fasting, and following a meal (postprandial). Participants were randomized in a 1:1 ratio to receive ranolazine or placebo, and were stratified by HbA1c ≤ 7.5% or \> 7.5%. Enrollment was to include no more than two-thirds of participants with baseline HbA1c ≤ 7.5%. Other than glucose values, efficacy endpoint results remained blinded during the study; for safety purposes, the investigator was to be alerted of severe hyperglycemia or hypoglycemia. Participants were instructed to maintain logs of their physical activity/exercise (Subject Activity Assessment) and study drug dosing (Dosing Log).

Diabetes Mellitus, Type 2

Gilead Sciences80 participantsStarted Jun 2010

Escondido, California, United States • Los Angeles, California, United States • Miami, Florida, United States +6 more locations

COMPLETED< 1 mile

OVATIO CRT and SITUS OTW LV Lead Post Approval Study

NCT00795873

Post approval study measuring safety outcomes on the Ovatio CRT-D and SITUS OTW LV lead over 5 years.

Heart Failure

ELA Medical, Inc.2,260 participantsStarted Dec 2008

Mesa, Arizona, United States • Mesa, Arizona, United States • Mesa, Arizona, United States +30 more locations

Exploratory Study to Access the Metabolic Effects of Ranolazine in Subjects With Type 2 Diabetes Mellitus When Added to Ongoing Non-insulin Antidiabetic Therapy

OVATIO CRT and SITUS OTW LV Lead Post Approval Study

Find Trials by Condition in Los Angeles

A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast Cancer

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) to Measure Response to Etanercept in Rheumatoid Arthritis

Omega-3 Fatty Acids in Preventing Breast Cancer in Women at High Risk of Developing Breast Cancer

Nutrition Intervention in Treating Women With Breast Cancer

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Kineflex Artificial Disc System to Treat Degenerative Disc Disease (DDD)

A Phase I Study of BIIB015 in Relapsed/Refractory Solid Tumors

TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus

A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain

Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception

Retrospective Patient Satisfaction Survey in Subjects With Tecnis Intra Ocular Lenses and Cataracts Surgery

A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients

Treatment Interruption of Natalizumab

Internet-Based Nutrition Education Program in Preventing Cancer in Participants of Health Maintenance Organizations